RSV Vaccine 90% Effective in High-Risk Adults, Real-World Study Shows
The bivalent RSV prefusion F vaccine (Abrysvo) demonstrated 90% vaccine effectiveness (VE) in high-risk adults against hospitalizations or emergency department (ED) visits associated with respiratory syncytial virus (RSV), according to recent real-world data presented at the IDWeek annual meeting in Los Angeles.
Since their introduction last year, researchers have been monitoring the real-world impact of the new respiratory syncytial ...
GSK on Wednesday said its vaccine sales would fall this year, after a weaker-than-expected performance for its respiratory ...
For adults aged 60 years or older, respiratory syncytial virus (RSV) vaccination is effective for preventing associat ...
Moderna said its newest Covid vaccine saw benefits after winning approval in the U.S. three weeks earlier than the last iteration of the shot did in 2023.
While Moderna’s Spikevax beat Wall Street estimates in the third quarter, William Blair analyst Myles Minter in a Thursday ...
Moderna reported a surprising third-quarter profit on Thursday, driven by cost reductions and stronger-than-expected sales of ...
News Medical on MSN13d
RSV Vaccines Work, Uptake Must RiseOlder people with RSV are at higher risk of severe illness compared to those with influenza or COVID. Vaccines Protect ...
The top-line beat was led by its higher than anticipated sales of Covid-19 vaccine, while its recently approved respiratory syncytial virus vaccine raked in just $10 ...
Doctors detail what we learned after the first season following the approval of RSV vaccines. The vaccine effectively prevented severe illness in older, but only 24 percent of eligible US adults ...
The other group at the highest risk when it comes to RSV is children under age five, and specifically infants—especially ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback